- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- pramlintide acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Concord, California • La Jolla, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 4,209
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Concord, California • Fresno, California + 4 more
- Conditions
- Rheumatoid Arthritis, Pharmacokinetics of ASP2408
- Interventions
- ASP2408, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Anniston, Alabama • Duncansville, Pennsylvania • Dallas, Texas
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- Adalimumab
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 45 Years to 80 Years · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Glenview, Illinois
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- antisense oligonucleotide, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- La Jolla, California • Rochester, Minnesota • Nashville, Tennessee
- Conditions
- Carpometacarpal (CMC) Osteoarthritis
- Interventions
- Triamcinolone Acetonide extended release suspension
- Drug
- Lead sponsor
- Marie Badalamente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Healthy
- Interventions
- CD388 Injection, Saline placebo
- Combination Product · Drug
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
- Interventions
- CTX0E03 Drug Product and delivery device, Placebo
- Combination Product · Drug
- Lead sponsor
- ReNeuron Limited
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more
- Conditions
- Cervical Dystonia
- Interventions
- botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline
- Biological · Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Atrial Flutter
- Interventions
- Vernakalant Injection 20 mg/mL
- Drug
- Lead sponsor
- Advanz Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 5
- States / cities
- Sacramento, California • Lansing, Michigan • Richmond, Virginia + 1 more
- Conditions
- Infertility (IVF Patients)
- Interventions
- hMG subcutaneous injection, Placebo
- Drug
- Lead sponsor
- Granata Bio Corporation
- Industry
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Encino, California • Norwalk, Connecticut • Newark, Delaware + 13 more
- Conditions
- Clear Cell Renal Carcinoma
- Interventions
- Trovax, Placebo, Standard of care therapy
- Biological
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 46
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
- Interventions
- taldefgrobep alfa, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more
- Conditions
- Osteoporosis
- Interventions
- PTH/Calcium, PTH/placebo, placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 17
- States / cities
- Rancho Cucamonga, California • Lake Worth, Florida • Coeur d'Alene, Idaho + 14 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- naloxone versus placebo, intravenous injection of normal saline or naloxone
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Alzheimer Disease
- Interventions
- AV-1959D, Placebo
- Biological
- Lead sponsor
- Institute for Molecular Medicine
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Newport Beach, California • Tampa, Florida + 3 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, Golimumab 50 mg, Golimumab 100 mg, Golimumab 200 mg
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 93 more
- Conditions
- Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Sclerosis
- Interventions
- SAR441344 IV, placebo IV, SAR441344 SC, placebo SC, MRI contrast-enhancing preparations
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more
- Conditions
- Acute HIV Infection
- Interventions
- VRC07-523LS, PGT121.414.LS, Placebo, ART
- Biological · Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- T. John Winhusen, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
- Conditions
- Postoperative Pain, Abdominal Surgery
- Interventions
- SABER-Bupivacaine, Bupivacaine HCl, SABER-Placebo
- Drug
- Lead sponsor
- Durect
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 18 more
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism
- Interventions
- Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more